Image source: Shutterstock

Highlights

  • Telix Pharmaceuticals reported a significant 56% year-on-year increase in revenue for FY24, reaching AUD 783.2 million.
  • Profit after tax surged 860% YoY to AUD 49.9 million in FY24, marking Telix’s second consecutive profitable year.
  • In Q1FY25, unaudited revenue hit AUD 186 million, a 62% YoY increase and a 31% rise over the previous quarter.
  • Telix reaffirmed its FY25 revenue guidance of AUD 770–800 million, supported by the RLS acquisition and ongoing Illuccix® sales.
  • The anticipated U.S. launch of Gozellix® in Q2 2025 is expected to support future revenue growth.

Melbourne-based Telix Pharmaceuticals Limited (ASX:TLX) is a biopharmaceutical company focused on developing and commercialising diagnostic and therapeutic radiopharmaceuticals. In the financial year 2024 (FY24), the company has reported a significant surge in revenue with momentum continuing in the first quarter of FY25 (1QFY25).

Financial performance in FY24

  • Revenue rose to AUD 783.2 million, up 56% from AUD 502.5 million in FY23.
  • Gross profit increased by 62%, reaching AUD 509.6 million.
  • Profit after tax surged to AUD 49.9 million, representing an 860% year-on-year growth.
  • Adjusted EBITDA jumped by 70%.

This healthy financial performance was largely attributed to higher sales of Illuccix®, which played a central role in driving top-line growth and marking Telix’s second consecutive year of profitability. The reported period saw the expansion of the product delivery infrastructure and global supply chain.

As of 31 December 2024, Telix’s cash reserves rose sharply to AUD 710.3 million, compared to AUD 123.2 million the previous year.

Positive Start to FY25 with First Quarter Growth

Building on the momentum from FY24, Telix reported unaudited revenue of AUD 186 million in Q1FY25, a 62% increase YoY and 31% growth over the previous quarter.
Key contributors included:

  • Illuccix®, delivering AUD 151 million in Q1 sales — up 35% from Q1 2024.
  • RLS Radiopharmacies, acquired in January 2025, which added AUD 33 million to the quarter's revenue.

FY25 Revenue Guidance

Telix has reaffirmed its FY25 revenue guidance of AUD 770–800 million, driven by continued Illuccix® sales and contributions from the RLS acquisition. The company also expects several strategic developments in the coming quarters:

  • The anticipated U.S. launch of Gozellix® in Q2 2025, a PSMA-PET imaging agent with extended shelf life, is expected to boost revenue.
  • Expansion of Illuccix® in Europe, the UK, and Brazil is likely to accelerate global sales and reinforce Telix’s leadership in key international diagnostics markets.

Telix has outlined plans to increase its R&D investment by 20–25% in FY25. This commitment supports the development of its innovation pipeline, particularly therapies such as TLX101 and TLX250, which targets various forms of cancer.

Stock Performance of TLX

TLX shares closed 1.30% higher at AUD 25.68 per share on 21 May 2025. In a year, TLX recorded 66.86% surge in its stock price, and on a year-to-date basis, it has increased by 4.35%.

52-week high of TLX is AUD 31.97, recorded on 26 February 2025 and 52-week low is AUD 14.42, recorded on 20 May 2024.

Support and Resistance Summary

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 21 May 2025. The reference data in this report has been partly sourced from EODHD/Others.

 

Technical Indicators Defined:

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.